SCHEMBL660435

SCHEMBL660435

O=Cc1nn(C2CCCCO2)c2ccc(Br)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
MAPK1 P28482 2/20 0.36
TP53 P04637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
RET P07949 2/20 0.35
CYP4F2 P78329 3/20 0.33
CYP4A11 Q02928 3/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.32
ATR Q13535 1/20 0.32
ALOX15 P16050 1/20 0.31
CNR2 P34972 3/20 0.31
CDK1 P06493 1/20 0.31
CNR1 P21554 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14658689 0.90 RET (0.35) ALDH1A1MAPTLMNAHTTMAPK1
SCHEMBL31473301 0.90 RET (0.35) ALDH1A1MAPTLMNAHTTMAPK1
SCHEMBL30673111 0.89 MAPT (0.36) ALDH1A1MAPTLMNAHTTMAPK1
SCHEMBL26924742 0.89 MAPT (0.36) ALDH1A1MAPTLMNAHTTMAPK1
SCHEMBL16100304 0.85 CYP4F2 (0.40) ALDH1A1LMNAHTTRXRARXRB
SCHEMBL16100177 0.85 CYP4F2 (0.40) ALDH1A1LMNAHTTRXRARXRB
SCHEMBL16881008 0.85 RXRA (0.35) ALDH1A1MAPTLMNAHTTMAPK1
SCHEMBL13558784 0.85 CYP4F2 (0.38) ALDH1A1MAPTLMNAMAPK1RXRA
SCHEMBL5809971 0.85 CYP4F2 (0.38) ALDH1A1LMNARXRARXRBRXRG
SCHEMBL30182911 0.85 MAPT (0.38) ALDH1A1MAPTLMNAHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
EP-4357347-B1 TRK KINASE INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-12-11 EP disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
US-20240317760-A1 TRK KINASE INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-09-26 US disclosed
CN-115043844-B TRK kinase inhibitor compounds and uses thereof 河南迈英诺医药科技有限公司 2024-05-17 CN disclosed
EP-4357347-A1 TRK KINASE INHIBITOR COMPOUND AND USE THEREOF Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) 2024-04-24 EP disclosed
EP-4351560-A1 ANTICANCER COMPOUNDS The Regents of the University of California (US) 2024-04-17 EP disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 CN disclosed
WO-2024040768-A1 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE 中国药科大学 2024-02-29 WO disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
US-8569511-B2 Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-10-29 US disclosed
US-8569511-B2 Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-10-29 US disclosed
US-8569511-B2 Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-10-29 US disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION 2012-11-01 US disclosed
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION 2012-11-01 US disclosed
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION 2012-11-01 US disclosed
WO-2012135799-A1 SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-10-04 WO disclosed
WO-2012135799-A1 SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-10-04 WO disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179059-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA ALDH1A1 3346/4885MAPT 2666/4885LMNA 4337/4885
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 ALDH1A1 1904/4885MAPT 66/4885LMNA 4077/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 ALDH1A1 490/4885MAPT 214/4885LMNA 3566/4885
US-20240317760-A1 TRK KINASE INHIBITOR COMPOUND AND USE THEREOF TTK, ROR1, MAP3K20 ALDH1A1 3767/4885MAPT 417/4885LMNA 1951/4885
US-20120277229-A1 SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE PDK1, PDK3, PDK2 ALDH1A1 2281/4885MAPT 2008/4885LMNA 2842/4885
US-12162870-B2 Anticancer compounds BET1, BRD4, BICRA ALDH1A1 3346/4885MAPT 2666/4885LMNA 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.